8.09
price up icon15.57%   1.09
after-market 시간 외 거래: 8.24 0.15 +1.85%
loading

Kala Bio Inc 주식(KALA)의 최신 뉴스

pulisher
Jul 25, 2025

KALA BIO Inc. Stock Analysis and ForecastHigh-yield trading alerts - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility - TradingView

Jul 25, 2025
pulisher
Jul 25, 2025

Is KALA BIO Inc. a good long term investmentHigh-velocity gains - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Should I buy KALA BIO Inc. stock before earningsHigh-performance investment picks - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about KALA BIO Inc. stockTremendous gains - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What drives KALA BIO Inc. stock priceOutstanding risk-reward balance - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Stellantis N.V. stockRemarkable growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is CURR a good long term investmentDynamic investment growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 20, 2025

KALA BIO (NASDAQ:KALA) Downgraded to “Sell” Rating by Wall Street Zen - Defense World

Jul 20, 2025
pulisher
Jul 15, 2025

What makes KALA BIO Inc. stock price move sharplyHigh Return Conservative Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why KALA BIO Inc. stock attracts strong analyst attentionMomentum Buy Alert - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How KALA BIO Inc. stock performs during market volatilityFree Wealth-Building Investment Strategies - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

All Eyes On KALA's CHASEWill The PCED Trial Make Its Case? - RTTNews

Jul 14, 2025
pulisher
Jul 14, 2025

Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis - Ophthalmology Times

Jul 14, 2025
pulisher
Jul 13, 2025

LADENBURG THALM/SH SH Initiates Coverage on KALA BIO (NASDAQ:KALA) - Defense World

Jul 13, 2025
pulisher
Jul 12, 2025

KALA Bio completes enrollment of CHASE clinical trial - Ophthalmology Times

Jul 12, 2025
pulisher
Jul 12, 2025

KALA BIO (NASDAQ:KALA) Upgraded by Wall Street Zen to Hold Rating - Defense World

Jul 12, 2025
pulisher
Jul 11, 2025

This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga

Jul 11, 2025
pulisher
Jul 11, 2025

Ladenburg Thalmann Initiates KALA BIO at Buy With $12 Price Target - MarketScreener

Jul 11, 2025
pulisher
Jul 11, 2025

Kala Pharmaceuticals (KALA) Receives Buy Rating from Ladenburg | KALA Stock News - GuruFocus

Jul 11, 2025
pulisher
Jul 10, 2025

Kala Pharmaceuticals (KALA) Receives Buy Rating from Ladenburg - GuruFocus

Jul 10, 2025
pulisher
Jul 09, 2025

Kala Bio Announces Completion of Enrollment in Chase Clinical Trial Evaluating Kpi-012 for the Treatment of Persistent Corneal Epithelial Defect - MarketScreener

Jul 09, 2025
pulisher
Jul 09, 2025

KALA Completes Patient Enrollment in Phase 2b CHASE Trial for KP - GuruFocus

Jul 09, 2025
pulisher
Jul 09, 2025

Kala Pharmaceuticals Completes Enrollment for Phase 2b Trial - TipRanks

Jul 09, 2025
pulisher
Jul 09, 2025

Kala Bio completes enrollment in Phase 2b trial for KPI-012 in eye disorder - Investing.com

Jul 09, 2025
pulisher
Jul 09, 2025

KALA BIO Completes Patient Enrollment in CHASE Phase 2b Trial for KPI-012, Anticipates Topline Results by Q3 2025 - Quiver Quantitative

Jul 09, 2025
pulisher
Jul 09, 2025

KALA BIO Announces Completion of Enrollment in CHASE - GlobeNewswire

Jul 09, 2025
pulisher
Jul 09, 2025

KALA BIO Eyes 100,000 Patient Market as Pivotal PCED Trial Completes Enrollment, Q3 Results Ahead - Stock Titan

Jul 09, 2025
pulisher
Jul 07, 2025

KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discu - GuruFocus

Jul 07, 2025
pulisher
Jul 07, 2025

KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to - GlobeNewswire

Jul 07, 2025
pulisher
Jul 07, 2025

KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) - Yahoo Finance

Jul 07, 2025
pulisher
Jun 26, 2025

KALA BIO Executives Sell Shares Under 10b5-1 Plans - TradingView

Jun 26, 2025
pulisher
Jun 06, 2025

Millennium Management LLC Purchases 17,130 Shares of HBT Financial, Inc. (NASDAQ:HBT) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Millennium Management LLC Decreases Stake in KALA BIO, Inc. (NASDAQ:KALA) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Nexa Resources S.A. (NYSE:NEXA) Shares Sold by Millennium Management LLC - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

24,353 Shares in T. Rowe Price Floating Rate ETF (NYSEARCA:TFLR) Acquired by Bank of America Corp DE - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Cadre Holdings, Inc. (NYSE:CDRE) Shares Acquired by Millennium Management LLC - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Bank of America Corp DE Acquires 2,612 Shares of First Trust Indxx Global Natural Resources Income ETF (NASDAQ:FTRI) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Millennium Management LLC Sells 1,791 Shares of Bluerock Homes Trust, Inc. (NYSEAMERICAN:BHM) - Defense World

Jun 06, 2025
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
자본화:     |  볼륨(24시간):